While we could not identify a definitive clinical profile of risk factors for calcinosis in our myositis patients, Fredi et al. considered anti-NXP-2 antibody as an independent predictive risk factor for calcinosis development (p = 0.024, OR 21.9, CI 95% = 1.5–319) [39]. Here, MORC3 is linked to calcinosis.